The molecular markers might be used for predicting the sensitivity of neoadjuvant chemotherapy of BC including ERBB2, Ki‐67, BRAC1, MDR1, ERCC1, GDPD3, SPRED1, etc.69, 70, 71, 72, 73 With the development of neoadjuvant chemotherapy agents, preservation treatment could be considered for BC patients who are sensitive to neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.